PharmaTimes | in-depth news, features and insights for the pharmaceutical and healthcare sectors

.tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end}[data-toolset-views-view-pagination-block="b5ee7a93952c82ad8154125da3a7733a"] ul { text-align: center;justify-content: center; } .tb-container .tb-container-inner{width:100%;margin:0 auto} .wp-block-toolset-blocks-container.tb-container[data-toolset-blocks-container="2c43613e993e2394568fe34903b86a0f"] { background:linear-gradient(rgba( 0, 0, 0, 0.13 ),rgba( 0, 0, 0, 0.13 )),   url('https://pharmatimes.com/wp-content/uploads/2023/12/AI.jpg') center center no-repeat;background-size:auto, cover;padding: 25px;min-height: 500px;display:ms-flexbox !important;display:flex !important;-ms-flex-direction:column;flex-direction:column;-ms-flex-pack:center;justify-content:center; } .tb-container .tb-container-inner{width:100%;margin:0 auto} .wp-block-toolset-blocks-container.tb-container[data-toolset-blocks-container="25729c831f4b8caf3a7382396af662f4"] { background: rgba( 110, 110, 110, 0.43 );padding: 15px 25px 15px 25px; } .tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em} .tb-button[data-toolset-blocks-button="37dad1b8a003c5dbbfa7f1938d6759a2"] .tb-button__link { background-color: rgba( 255, 255, 255, 0 );color: rgba( 255, 255, 255, 1 );border: 2px solid rgba( 255, 255, 255, 1 );font-weight: bold;color: rgba( 255, 255, 255, 1 ); } .tb-container .tb-container-inner{width:100%;margin:0 auto}h2.tb-heading[data-toolset-blocks-heading="3b7ed8e4afda9e2b6b6174785a4c06c4"]  { font-size: 42px;font-family: Merriweather;font-weight: bold;color: rgba( 255, 255, 255, 1 );text-align: left; }  @media only screen and (max-width: 781px) { .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end}.tb-container .tb-container-inner{width:100%;margin:0 auto}.tb-container .tb-container-inner{width:100%;margin:0 auto}.tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em}.tb-container .tb-container-inner{width:100%;margin:0 auto}  } @media only screen and (max-width: 599px) { .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end}.tb-container .tb-container-inner{width:100%;margin:0 auto}.tb-container .tb-container-inner{width:100%;margin:0 auto}.tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em}.tb-container .tb-container-inner{width:100%;margin:0 auto}  } 

SUSAR coated

Safety case processing could make SUSAR timelines obsolete

News

Johnson & Johnson reports phase 2 data showing nipocalimab reduced SLE disease activity

Jun 4, 2026

Late‑breaking EULAR results highlight sustained responses through week 52

European approval enables measles protection with CSL’s immunoglobulin Privigen

Jun 4, 2026

Commission authorisation expands access to passive measles prophylaxis for vulnerable patients

JJP Biologics reports positive interim phase 1b data for nebaprubart

Jun 3, 2026

Early clinical activity supports expansion into broader IgA‑mediated conditions

Immunotherapy boost can spare more bladder cancer patients major surgery

Jun 3, 2026

Adding durvalumab to chemoradiation helps people avoid having their bladder removed

Deep Science Ventures and MDC partner to accelerate brain treatments

Jun 2, 2026

New collaboration aims to break barriers in brain‑targeted drug discovery

Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb

Jun 2, 2026

Aragen scales Daretabart to commercial-ready production following rapid 9‑month tech transfer

Web Exclusives

True colours

Jan 15, 2026

The gold standard in spectroscopy

Trust issues

Oct 24, 2025

Specialty pharmacies – a guide to regulatory bodies and standards

Leader of the packs

Oct 1, 2025

3 Packaging Companies that offer custom pharmaceutical packaging solutions

Fertile ground

Aug 24, 2025

Top-rated pharmacies in northern Virginia for personalised fertility care

Magazine

June 2026

Jun 5, 2026

This issue reminds us that humankind remains the enduring question, and diversity in clinical trials is the answer (even if machine learning hops on for the ride!). We’ve also got features reflecting healthcare and society: health comms meets stand-up comedy, the chaos of probiotics, and medicine governance in focus. Plus a report on the PharmaTimes Clinical Researcher of the Year Awards, and the GLP-1 tour rolls on.